Breaking News, Collaborations & Alliances

Sciwind Biosciences and Verdiva Bio Enter Global Licensing Agreement

Grants Verdiva Bio exclusive global rights (excluding Greater China and South Korea) to develop and commercialize its portfolio of metabolic disease therapies.

Author Image

By: Charlie Sternberg

Associate Editor

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing therapies to treat metabolic diseases, has announced a licensing and collaboration agreement for the global development and commercialization of a portfolio of metabolic diseases therapies in territories outside of Greater China and South Korea, with Verdiva Bio Limited, a clinical-stage biopharmaceutical company specialized in developing treatments for obesity and other cardiometabolic disorders....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics